Wed 5/22/2013 13:00 ET
DJIA15483.6396.000.62%SOLAR25.250.582.28%GOLD1372.704.900.36%Shanghai2302.402.760.12%
S&P 5001679.069.910.59%BANKS20.220.180.88%OIL94.941.241.29%Nikkei15627.26250.041.60%
NASDAQ3514.0311.950.34%SEMI38.660.100.26%US/EU0.780.000.35%Futures1675.7010.100.60%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Wall Street Pit (REXAHN PHARMACEUTICL - RNN)    Stock Due Diligence for All

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add RNN
  
From: darius (Rep: 101)Date: 02/19/2013 15:06
Forum: Wall Street Pit - Msg #2351968 - List RNN msgs Thread #673503149 (Rec: 0)
NEWS TODAY

Rexahn Pharmaceuticals provides key goals for 2013; expects to Initiate a Phase I clinical study with RX-5902 (RNN) 0.38 : Co continues to explore potential strategic partnerships to accelerate the development of its oncology pipeline. Rexahn's pipeline of innovative oncology compounds features six potential best-in-class compounds -- three clinical stage compounds (Archexin, RX-3117 (already partnered with Teva Pharmaceuticals), and RX-5902) and three pre-clinical compounds (RX-21101, RX-0047-N, and RX-0201-N). Each of these compounds offers an opportunity for a partner to bolster its oncology portfolio with differentiated assets possessing high potential clinical value.

Share This Post:


NOTE: This message has been revised 1 time. Read original version of this message.
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser darius: Reward | Watch | IgnoreRNN: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add RNN
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.